6-Aminoindene | 75476-87-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 6-Aminoindene
• 英文别名: 1H-inden-6-amine；3H-inden-5-amine
• CAS: 75476-87-8
• 化学式: C₉H₉N
• mdl: MFCD19206941
• 分子量: 131.177
• InChiKey: VUDZUYBRPVZLQY-UHFFFAOYSA-N

物化性质

• 沸点：
  279.3±29.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-Aminoindene 在 硫酸 、 potassium iodide 、 sodium nitrite 作用下， 反应 0.7h， 生成 6-碘异喹啉
  参考文献：
  名称：

  Synthesis of isoquinolines from indenes

  摘要：

  DOI：

  10.1021/jo01314a019
• 作为产物：
  描述：

  5-Nitroindan-1-ol 在 sulfurated sodium borohydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 19.0h， 生成 6-Aminoindene
  参考文献：
  名称：

  Synthesis of isoquinolines from indenes

  摘要：

  DOI：

  10.1021/jo01314a019

文献信息

• Synthesis of haloindenes
  申请人：Wnuk Stanislaw F.

  公开号：US10954178B1

  公开（公告）日：2021-03-23

  The subject invention provides an expedited synthesis of 5, 6, and 7-iodoindenes from the corresponding aminoindan-1-ones in more than 70% yield, employing readily available precursors and reagents. A three-step sequence involves diazotization-iodination of aminoindan-1-one followed by reduction and dehydration. The method has a general character and can be extended for the preparation of various 4-, 5-, 6- or 7-haloindenes using different halogen sources for diazotization-halogenation reaction.

  该发明提供了一种从相应的氨基茚-1-酮中合成5、6和7-碘茚的快速合成方法，收率超过70％，利用易得的前体和试剂。三步序列包括氨基茚-1-酮的重氮化-碘化，随后进行还原和脱水。该方法具有一般性质，可以通过使用不同卤素源进行重氮化-卤代反应来扩展，用于制备各种4、5、6或7-卤代茚。
• Antidiabetic bicyclic compounds
  申请人：Ge Min

  公开号：US20070265332A1

  公开（公告）日：2007-11-15

  Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  含有环丙基羧酸或羧酸衍生物（如酰胺）的三环化合物与融合到双环环上的G蛋白偶联受体40（GPR40）是激动剂，并且可用作治疗化合物，特别是在治疗2型糖尿病方面，以及与该疾病常相关的病症，包括肥胖和脂质紊乱，如混合性或糖尿病性脂质代谢异常、高血脂、高胆固醇血症和高甘油三酯血症。
• Urokinase inhibitors
  申请人：——

  公开号：US20010049374A1

  公开（公告）日：2001-12-06

  Compounds having the formula 1 are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

  化合物的化学式为1，它们是尿激酶抑制剂，在尿激酶发挥作用的疾病治疗中有用。还披露了抑制尿激酶的组合物和一种在哺乳动物中抑制尿激酶的方法。
• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Pauls Heinz W.

  公开号：US20110065702A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其结构式表示为(A)或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式(A)所表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗患有癌症的受试者的方法，其中该方法包括给予上述结构式(A)所表示的化合物或其药学上可接受的盐的治疗有效量。
• ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION
  申请人：SIGA TECHNOLOGIES INC.

  公开号：US20150023916A1

  公开（公告）日：2015-01-22

  Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.

  本发明揭示了通过以治疗有效的剂量给予某些化合物来治疗病毒感染的化合物、方法和制药组合物。还揭示了制备这些化合物的方法以及使用这些化合物和其制药组合物的方法。特别是治疗和预防由Arenavirus家族引起的病毒感染，例如拉沙热、阿根廷出血热、玻利维亚出血热和委内瑞拉出血热。